Clinical application of the HE4, CA125 and CYFRA21-1 combined detection in the diagnosis of malignant ovarian tumor

doi:10.3969/j.issn.1673-8640.2014.07.001

Abstract

Abstract:

Objective　To investigate the clinical significance of human epididymis 4（HE4）， carbohydrate antigen 125（CA125） and cytokeratin-19-fragment（CYFRA21-1） combined detection in the diagnosis of malignant ovarian tumor. Methods　The sera of 85 patients with malignant ovarian tumor， 85 patients with benign ovarian tumor and 85 healthy women（healthy control group） were collected. The serum levels of HE4 were determined by enzyme-linked immunosorbent assay（ELISA）. The serum levels of CA125 and CYFRA21-1 were determined by chemiluminescence assay. The results of the 3 biomarkers were analyzed comparatively in different groups， and the positive rates of the 3 individual detections and the combined detection were analyzed. Results　Serum HE4， CA125 and CYFRA21-1 levels in malignant ovarian tumor group were significantly higher than those in benign ovarian tumor group and healthy control group（P＜0.01）. The positive rates of HE4， CA125， CYFRA21-1 and the combined detection of the 3 biomarkers were 88.24%， 74.12%， 77.65% and 98.82%， respectively. Conclusions　The combined detection of HE4， CA125 and CYFRA21-1 shows the good auxiliary diagnosis significance for malignant ovarian tumor.

Key words: Human epididymis 4, Carbohydrate antigen 125, Cytokeratin-19-fragment, Malignant ovarian tumor

CLC Number:

R446.62

TIAN Feng,YI Menglu,QI Suwen,WANG Linxian. Clinical application of the HE4, CA125 and CYFRA21-1 combined detection in the diagnosis of malignant ovarian tumor[J]. , 2014, 29(7): 697-700.

References

[1] 李巍,崔恒,冯捷,等.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498.
[2] Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2009,112(1): 40-46.
[3] 李青,宋晓玲,吴祺琰,等. HE4与CA125联合检测在卵巢癌与卵巢子宫内膜异位囊肿鉴别诊断中的临床应用[J]. 现代肿瘤医学, 2013, 21(2):389-392.
[4] Manolov V, Marinov B, Vasilev V. HE4 and CA125 in ovarian cancer [J].Akush Ginekol (Sofiia), 2012, 51(2):21-28.
[5] Yang Z, Wei C, Luo Z, et al. Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis [J]. Onco Targets Ther, 2013, 6:957-966.
[6] 李仙丽,冯显红,李海芬,等. 卵巢癌的生物学标志物的分析与探讨[J].实用临床医学, 2011,12(3):3-5.
[7] 连利娟,林巧稚.妇科肿瘤学[M].第4版.北京:人民卫生出版社,2006:410-461.
[8] 毛佩敏,刘晓艳. 血清CA125测定对卵巢高、低级别浆液性癌鉴别诊断价值的回顾性研究[J]. 检验医学, 2012, 27(7):592-594.
[9] 吴琼.卵巢癌相关肿瘤标志物的研究进展[J].实用医学杂志,2011, 27(8):1499-1450.
[10] Steffensen KD, Waldstrm M, Brandslund I, et al.The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients[J]. Int J Gynecol Cancer, 2012, 22(9):1474-1482.
[11] Pitta Dda R, Sarian LO, Barreta A, et al. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses [J]. BMC Cancer, 2013, 13:423.
[12] Kaijser J, Van Gorp T, Van Hoorde K, et al. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm(ROMA) to assess the risk of malignancy in women with an adnexal mass[J]. Gynecol Oncol, 2013, 129(2):377-383.

[1]	YANG Chaomei, FENG Jie, LANG Lei, YAN Guangtao. Clinical application value of CTC combined determination with CEA and CA125 in colorectal cancer [J]. Laboratory Medicine, 2021, 36(9): 901-905.
[2]	ZENG Ruihuang, WANG Xiaolin, ZENG Ye, CHEN Zhixi, YUAN Ning, QIN Changhong. Roles of CA125,NLR,PLR and hs-CRP combined determination for community-acquired pneumonia with pleural effusion based on datum mining model [J]. Laboratory Medicine, 2020, 35(11): 1103-1107.
[3]	WANG Zhiheng, YING Chunmei. Changes of CA125 in pregnancy and relationship with other biochemical indicators [J]. Laboratory Medicine, 2019, 34(8): 687-690.
[4]	ZHANG Liying, FU Guanhua, WU Junqi. Roles of 4 serum tumor markers for the auxiliary diagnosis and efficacy evaluation of lung cancer [J]. Laboratory Medicine, 2019, 34(4): 331-334.
[5]	HE Hua, HU Rong, LI Feng, ZHU Yafei, REN Ling, JIANG Lixia. Reference intervals of serum HE4 and ROMA index determined by electrochemiluminescence [J]. Laboratory Medicine, 2017, 32(5): 399-402.
[6]	ZHAO Xuhong, HUO Meng, YANG Miao, HOU Junlin. Changes of indices for lymphangioleiomyomatosis [J]. Laboratory Medicine, 2016, 31(6): 509-512.
[7]	SONG Binbin, PAN Baishen. Clinical application of serum biomarkers for ovarian cancer [J]. Laboratory Medicine, 2015, 30(8): 866-870.
[8]	WU Ping, YE Weimin, LI Chen, XIA Xiaohong, ZHANG Zhencheng, ZHAO Wenjing, CUI Yanfang, ZHANG Caiying, ZHONG Renqian, YANG Zaixing. Research on the diagnosis significance of human epididymis protein 4 for chronic kidney disease [J]. Laboratory Medicine, 2015, 30(5): 461-464.
[9]	MAO Peimin;LIU Xiaoyan. A retrospective descriptive study on the significance of carbohydrate antigen 125 in differential diagnosis of high and low grade serous ovarian cancer [J]. , 2012, 27(7): 592-594.